Refine by
Who Standard Articles & Analysis
9 news found
” “When mProbe and xCures join forces in the fight against advanced cancer by offering integrated treatment plans which leverage targeted proteomics, precision diagnostics, artificial intelligence, and predictive modeling, we are giving hope to advanced cancer patients who have exhausted the standard of care.” said Peter Chen, CEO of mProbe. ...
ByxCures
"The emerging data being presented at ESMO are encouraging, as treatment with rigosertib plus nivolumab led to both complete and partial responses in patients with KRAS-mutated lung cancers who failed prior ICI therapy,” said Dr Rajwanth Veluswamy, the principal investigator of the study. ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
The 43 patients were comprised of 20 persons who received single-vector HB-201 and 23 who received alternating 2-vector HB-202/HB-201. ...
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) provide initial ...
The presentation titled, “Phase 1 Study of Intravitreal UBX1325: A Novel Agent Against Retinal Cell Senescence in AMD and DME,” featured safety, efficacy, and durability data from the Phase 1 single ascending dose study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), including data results from the AMD expansion cohort ...
” Third Quarter and Recent Corporate Developments Signed a clinical trial collaboration agreement with Arbutus Biopharma Corporation to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus infection (CHB) who are already receiving standard-of-care nucleoside or nucleotide analog (NA) therapy. ...
In the light of the new variants, BOHS underlines the importance of observing good ventilation and full air changes in line at least with the WHO standards Coronavirus disease (COVID-19): Ventilation and air conditioning in health facilities (who.int). For healthcare workers, including dentists, who may be exposed to locations which have been ...
The new facilities will increase production capacity substantially while simultaneously ensuring compliance with future WHO demands for Polio vaccine production and containment. AJ Vaccines and the company’s owner have decided to initiate a comprehensive and needed upgrade of the production facilities in Copenhagen – not least to be able to meet the large global ...